Publications

  1. Ma CX, Suman V, Goetz MP, Northfelt D, Burkard ME, Ademuyiwa F, Naughton M, Margenthaler J, Aft R, Gray R, Tevaarwerk A, Wilke L, Haddad T, Moynihan T, Loprinzi C, Hieken T, Barnell EK, Skidmore ZL, Feng YY, Krysiak K, Hoog J, Guo Z, Nehring L, Wisinski KB, Mardis E, Hagemann IS, Vij K, Sanati S, Al-Kateb H, Griffith OL, Griffith M, Doyle L, Erlichman C, Ellis MJ. A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer. Clin Cancer Res. 2017 Nov 15; 23 (22):6823-6832 Epub 2017 Sept 05
    View PubMed
  2. Goetz MP, Suman VJ, Reid JM, Northfelt DW, Mahr MA, Ralya AT, Kuffel M, Buhrow SA, Safgren SL, McGovern RM, Black J, Dockter T, Haddad T, Erlichman C, Adjei AA, Visscher D, Chalmers ZR, Frampton G, Kipp BR, Liu MC, Hawse JR, Doroshow JH, Collins JM, Streicher H, Ames MM, Ingle JN. First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer. J Clin Oncol. 2017 Oct 20; 35 (30):3391-3400 Epub 2017 Aug 30
    View PubMed
  3. Haricharan S, Punturi N, Singh P, Holloway KR, Anurag M, Schmelz J, Schmidt C, Lei JT, Suman V, Hunt K, Olson JA Jr, Hoog J, Li S, Huang S, Edwards DP, Kavuri SM, Bainbridge MN, Ma CX, Ellis MJ. Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer. Cancer Discov. 2017 Oct; 7 (10):1168-1183 Epub 2017 Aug 11
    View PubMed
  4. Doostan I, Karakas C, Kohansal M, Low KH, Ellis MJ, Olson JA Jr, Suman VJ, Hunt KK, Moulder SL, Keyomarsi K. Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. Clin Cancer Res. 2017 Sep 25 Epub 2017 Sept 25
    View PubMed
  5. Jasim S, Suman VJ, Jimenez C, Harris P, Sideras K, Burton JK, Worden FP, Auchus RJ, Bible KC. Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma. Endocrine. 2017 Aug; 57: (2)220-225.
    View PubMed
  6. Goetz MP, Kalari KR, Suman VJ, Moyer AM, Yu J, Visscher DW, Dockter TJ, Vedell PT, Sinnwell JP, Tang X, Thompson KJ, McLaughlin SA, Moreno-Aspitia A, Copland JA, Northfelt DW, Gray RJ, Hunt K, Conners A, Sicotte H, Eckel-Passow JE, Kocher JP, Ingle JN, Ellingson MS, McDonough M, Wieben ED, Weinshilboum R, Wang L, Boughey JC. Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer. J Natl Cancer Inst. 2017 Jul 01; 109 (7)
    View PubMed
  7. Lesurf R, Griffith OL, Griffith M, Hundal J, Trani L, Watson MA, Aft R, Ellis MJ, Ota D, Suman VJ, Meric-Bernstam F, Leitch AM, Boughey JC, Unzeitig G, Buzdar AU, Hunt KK, Mardis ER. Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial. Ann Oncol. 2017 May 01; 28 (5):1070-1077
    View PubMed
  8. Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, DeSchryver K, Crouch E, Brink A, Watson M, Luo J, Tao Y, Barnes M, Dowsett M, Budd GT, Winer E, Silverman P, Esserman L, Carey L, Ma CX, Unzeitig G, Pluard T, Whitworth P, Babiera G, Guenther JM, Dayao Z, Ota D, Leitch M, Olson JA Jr, Allred DC, Hunt K. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol. 2017 Apr 01; 35 (10):1061-1069 Epub 2017 Jan 03
    View PubMed
  9. Lesurf R, Griffith OL, Griffith M, Hundal J, Trani L, Watson MA, Aft R, Ellis MJ, Ota D, Suman VJ, Meric-Bernstam F, Leitch AM, Boughey JC, Unzeitig G, Buzdar AU, Hunt KK, Mardis ER. Genomic characterisation of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy - results from the ACOSOG Z1041 (Alliance) trial. Ann Oncol. 2017 Feb 21;
    View PubMed
  10. Freedman RA, Seisler DK, Foster JC, Sloan JA, Lafky JM, Kimmick GG, Hurria A, Cohen HJ, Winer EP, Hudis CA, Partridge AH, Carey LA, Jatoi A, Klepin HD, Citron M, Berry DA, Shulman LN, Buzdar AU, Suman VJ, Muss HB. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). Breast Cancer Res Treat. 2017 Jan; 161 (2):363-373 Epub 2016 Nov 19
    View PubMed
  11. Jakub JW, Terando AM, Sarnaik A, Ariyan CE, Faries MB, Zani S Jr, Neuman HB, Wasif N, Farma JM, Averbook BJ, Bilimoria KY, Grotz TE, Allred JB, Suman VJ, Brady MS, Tyler D, Wayne JD, Nelson H. Safety and Feasibility of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma (SAFE-MILND): Report of a Prospective Multi-institutional Trial. Ann Surg. 2017 Jan; 265: (1)192-196.
    View PubMed
  12. Miller CA, Gindin Y, Lu C, Griffith OL, Griffith M, Shen D, Hoog J, Li T, Larson DE, Watson M, Davies SR, Hunt K, Suman VJ, Snider J, Walsh T, Colditz GA, DeSchryver K, Wilson RK, Mardis ER, Ellis MJ. Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers. Nat Commun. 2016 Aug 09; 7:12498
    View PubMed
  13. Park JH, Jang M, Tarhan YE, Katagiri T, Sasa M, Miyoshi Y, Kalari KR, Suman VJ, Weinshilboum R, Wang L, Boughey JC, Goetz MP, Nakamura Y. Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. Int J Oncol. 2016 Aug; 49: (2)471-8.
    View PubMed
  14. Gertz MA, Lacy MQ, Dispenzieri A, Buadi FK, Dingli D, Hayman SR, Kumar SK, Leung N, Lust J, Rajkumar SV, Russell SJ, Suman VJ, Le-Rademacher JG, Hogan WJ. Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis. Cancer. 2016 Jul 15; 122: (14)2197-205.
    View PubMed
  15. Gonzalez AB, Jakub JW, Harmsen WS, Suman VJ, Markovic SN. Status of the Regional Nodal Basin Remains Highly Prognostic in Melanoma Patients with In-Transit Disease. J Am Coll Surg. 2016 Jul; 223: (1)77-85.e1.
    View PubMed
  16. Pathangey LB, Lakshminarayanan V, Suman VJ, Pockaj BA, Mukherjee P, Gendler SJ. Aberrant Glycosylation of Anchor-Optimized MUC1 Peptides Can Enhance Antigen Binding Affinity and Reverse Tolerance to Cytotoxic T Lymphocytes. Biomolecules. 2016 Jun 29; 6 (3) Epub 2016 June 29
    View PubMed
  17. Porrata LF, Burgstaler EA, Winters JL, Jacob EK, Gastineau DA, Suman VJ, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nevala W, Markovic SN. Immunologic Autograft Engineering and Survival in Non-Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2016 Jun; 22 (6):1017-1023 Epub 2016 Jan 27
    View PubMed
  18. Jakub JW, Terando AM, Sarnaik A, Ariyan CE, Faries MB, Zani S Jr, Neuman HB, Wasif N, Farma JM, Averbook BJ, Bilimoria KY, Allred JB, Suman VJ, Grotz TE, Zendejas B, Wayne JD, Tyler DS. Training High-Volume Melanoma Surgeons to Perform a Novel Minimally Invasive Inguinal Lymphadenectomy: Report of a Prospective Multi-Institutional Trial. J Am Coll Surg. 2016 Mar; 222 (3):253-60 Epub 2015 Nov 25
    View PubMed
  19. Jakub JW, Terando AM, Sarnaik A, Ariyan CE, Faries MB, Zani S Jr, Neuman HB, Wasif N, Farma JM, Averbook BJ, Bilimoria KY, Grotz TE, Allred JB, Suman VJ, Brady MS, Tyler D, Wayne JD, Nelson H. Safety and Feasibility of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma (SAFE-MILND): Report of a Prospective Multi-institutional Trial. Ann Surg. 2016 Feb 25;
    View PubMed
  20. Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J, Blake C, Tlsty T, Vachon CM, Melton LJ, Visscher DW. Benign breast disease and the risk of breast cancer Obstetrical and Gynecological Survey. 2016; 71: (8)472-3.
  21. Ellingson MS, Hart SN, Kalari KR, Suman V, Schahl KA, Dockter TJ, Felten SJ, Sinnwell JP, Thompson KJ, Tang X, Vedell PT, Barman P, Sicotte H, Eckel-Passow JE, Northfelt DW, Gray RJ, McLaughlin SA, Moreno-Aspitia A, Ingle JN, Moyer AM, Visscher DW, Jones K, Conners A, McDonough M, Wieben ED, Wang L, Weinshilboum R, Boughey JC, Goetz MP. Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy. Breast Cancer Res Treat. 2015 Sep; 153: (2)435-43.
    View PubMed
  22. Suman VJ, Ellis MJ, Ma CX. The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2- invasive breast cancer. Chin Clin Oncol. 2015 Sep; 4 (3):34
    View PubMed
  23. Meves A, Nikolova E, Heim JB, Squirewell EJ, Cappel MA, Pittelkow MR, Otley CC, Behrendt N, Saunte DM, Lock-Andersen J, Schenck LA, Weaver AL, Suman VJ. Tumor Cell Adhesion As a Risk Factor for Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma. J Clin Oncol. 2015 Aug 10; 33: (23)2509-15.
    View PubMed
  24. Safgren SL, Suman VJ, Kosel ML, Gilbert JA, Buhrow SA, Black JL, Northfelt DW, Modak AS, Rosen D, Ingle JN, Ames MM, Reid JM, Goetz MP. Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen. Pharmacogenet Genomics. 2015 Apr; 25: (4)157-63.
    View PubMed
  25. Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Flippo-Morton TS, Kuerer HM, Bowling M, Hunt KK, Alliance for Clinical Trials in Oncology. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). Ann Surg. 2015 Mar; 261 (3):547-52
    View PubMed
  26. Goetz MP, Sun JX, Suman VJ, Silva GO, Perou CM, Nakamura Y, Cox NJ, Stephens PJ, Miller VA, Ross JS, Chen D, Safgren SL, Kuffel MJ, Ames MM, Kalari KR, Gomez HL, Gonzalez-Angulo AM, Burgues O, Brauch HB, Ingle JN, Ratain MJ, Yelensky R. Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies. J Natl Cancer Inst. 2014 Dec 08; 107 (2)
    View PubMed
  27. Reid JM, Goetz MP, Buhrow SA, Walden C, Safgren SL, Kuffel MJ, Reinicke KE, Suman V, Haluska P, Hou X, Ames MM. Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies. Cancer Chemother Pharmacol. 2014 Dec; 74: (6)1271-8.
    View PubMed
  28. Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014 Nov 20; 32 (33):3744-52 Epub 2014 Oct 20
    View PubMed
  29. Reese JM, Suman VJ, Subramaniam M, Wu X, Negron V, Gingery A, Pitel KS, Shah SS, Cunliffe HE, McCullough AE, Pockaj BA, Couch FJ, Olson JE, Reynolds C, Lingle WL, Spelsberg TC, Goetz MP, Ingle JN, Hawse JR. ERbeta1: characterization, prognosis, and evaluation of treatment strategies in ERalpha-positive and -negative breast cancer. BMC Cancer. 2014 Oct 07; 14:749.
    View PubMed
  30. Allen SV, Pruthi S, Suman VJ, Hoskin TL, Vachon CM, Ingle JN, Olson JE. Evaluation of the Aromatase Inhibition Potential of Freeze-Dried Grape Powder. J Diet Suppl. 2014 Aug 28;
    View PubMed
  31. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Karlin N, Sideras K, Morris JC 3rd, McIver B, Hay I, Fatourechi V, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Cher Goh B, Isham CR, Harris P, Erlichman C, Endocrine Malignancies Disease Oriented Group, Mayo Clinic Cancer Center, and the Mayo Phase 2 Consortium. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab. 2014 May; 99: (5)1687-93.
    View PubMed
  32. Province MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, Whaley R, Suman VJ, Schroth W, Winter S, Zembutsu H, Mushiroda T, Newman WG, Lee MT, Ambrosone CB, Beckmann MW, Choi JY, Dieudonne AS, Fasching PA, Ferraldeschi R, Gong L, Haschke-Becher E, Howell A, Jordan LB, Hamann U, Kiyotani K, Krippl P, Lambrechts D, Latif A, Langsenlehner U, Lorizio W, Neven P, Nguyen AT, Park BW, Purdie CA, Quinlan P, Renner W, Schmidt M, Schwab M, Shin JG, Stingl JC, Wegman P, Wingren S, Wu AH, Ziv E, Zirpoli G, Thompson AM, Jordan VC, Nakamura Y, Altman RB, Ames MM, Weinshilboum RM, Eichelbaum M, Ingle JN, Klein TE, International Tamoxifen Pharmacogenomics Consortium. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther. 2014 Feb; 95: (2)216-27.
    View PubMed
  33. D'Assoro AB, Liu T, Quatraro C, Amato A, Opyrchal M, Leontovich A, Ikeda Y, Ohmine S, Lingle W, Suman V, Ecsedy J, Iankov I, Di Leonardo A, Ayers-Inglers J, Degnim A, Billadeau D, McCubrey J, Ingle J, Salisbury JL, Galanis E. The mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERalpha(+) breast cancer cells. Oncogene. 2014 Jan 30; 33: (5)599-610.
    View PubMed
  34. Hawse JR, Pitel KS, Cicek M, Philbrick KA, Gingery A, Peters KD, Syed FA, Ingle JN, Suman VJ, Iwaniec UT, Turner RT, Spelsberg TC, Subramaniam M. TGFbeta inducible early gene-1 plays an important role in mediating estrogen signaling in the skeleton. J Bone Miner Res. 2014; 29: (5)1206-16.
    View PubMed
  35. Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig G, Royce M, McCall LM, Ewer MS, Hunt KK, American College of Surgeons Oncology Group investigators. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol. 2013 Dec; 14(13):1317-25. Epub 2013 Nov 13
    View PubMed
  36. Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Kuerer HM, Bowling M, Flippo-Morton TS, Byrd DR, Ollila DW, Julian TB, McLaughlin SA, McCall L, Symmans WF, Le-Petross HT, Haffty BG, Buchholz TA, Nelson H, Hunt KK, Alliance for Clinical Trials in Oncology. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013 Oct 09; 310: (14)1455-61.
    View PubMed
  37. Ma CX, Suman VJ, Goetz M, Haluska P, Moynihan T, Nanda R, Olopade O, Pluard T, Guo Z, Chen HX, Erlichman C, Ellis MJ, Fleming GF. A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat. 2013 May; 139: (1)145-53.
    View PubMed
  38. Vachon CM, Suman VJ, Brandt KR, Kosel ML, Buzdar AU, Olson JE, Wu FF, Flickinger LM, Ursin G, Elliott CR, Shepherd L, Weinshilboum RM, Goss PE, Ingle JN. Mammographic breast density response to aromatase inhibition. Clin Cancer Res. 2013 Apr 15; 19: (8)2144-53.
    View PubMed
  39. Cheville AL, Brinkmann DH, Ward SB, Durski J, Laack NN, Yan E, Schomberg PJ, Garces YI, Suman VJ, Petersen IA. The addition of SPECT/CT lymphoscintigraphy to breast cancer radiation planning spares lymph nodes critical for arm drainage. Int J Radiat Oncol Biol Phys. 2013 Mar 15; 85: (4)971-7.
    View PubMed
  40. Kottschade LA, Suman VJ, Perez DG, McWilliams RR, Kaur JS, Amatruda TT 3rd, Geoffroy FJ, Gross HM, Cohen PA, Jaslowski AJ, Kosel ML, Markovic SN. A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775. Cancer. 2013 Feb 01; 119: (3)586-92.
    View PubMed
  41. Goetz MP, Suman VJ, Hoskin TL, Gnant M, Filipits M, Safgren SL, Kuffel M, Jakesz R, Rudas M, Greil R, Dietze O, Lang A, Offner F, Reynolds CA, Weinshilboum RM, Ames MM, Ingle JN. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res. 2013 Jan 15; 19: (2)500-7.
    View PubMed
  42. Isham CR, Bossou AR, Negron V, Fisher KE, Kumar R, Marlow L, Lingle WL, Smallridge RC, Sherman EJ, Suman VJ, Copland JA, Bible KC. Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer. Sci Transl Med. 2013 Jan 02; 5: (166)166ra3.
    View PubMed
  43. Pruthi S, Yang L, Sandhu NP, Ingle JN, Beseler CL, Suman VJ, Cavalieri EL, Rogan EG. Evaluation of serum estrogen-DNA adducts as potential biomarkers for breast cancer risk. J Steroid Biochem Mol Biol. 2012 Oct; 132: (1-2)73-9.
    View PubMed
  44. Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ, Nevala WK, Thompson MA, Lewis JE, Rumilla KM, Roulstone V, Harrington K, Linette GP, Maples WJ, Coffey M, Zwiebel J, Kendra K. Phase II trial of intravenous administration of Reolysin((R)) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther. 2012 Oct; 20: (10)1998-2003.
    View PubMed
  45. Jatoi A, Allred JB, Suman VJ, Creagan ET, Croghan GA, Amatruda T, Markovic SN. Is Age >= 70 Years an Important Predictor of Adverse Events Among Patients Enrolled in Metastatic Melanoma Trials? Findings from Pooled Analyses of Therapeutic Trials. J Geriatr Oncol. 2012 Oct 01; 3: (4)307-311.
    View PubMed
  46. Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ, Nevala WK, Thompson MA, Lewis JE, Rumilla KM, Roulstone V, Harrington K, Linette GP, Maples WJ, Coffey M, Zwiebel J, Kendra K. Phase II Trial of Intravenous Administration of Reolysin(R) (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma. Mol Ther. 2012 Oct; 20: (10)1998-2003.
    View PubMed
  47. Bible KC, Suman VJ, Menefee ME, Smallridge RC, Molina JR, Maples WJ, Karlin NJ, Traynor AM, Kumar P, Goh BC, Lim WT, Bossou AR, Isham CR, Webster KP, Kukla AK, Bieber C, Burton JK, Harris P, Erlichman C, Mayo Phase 2 Consortium//Mayo Clinic Endocrine Malignances Disease Oriented Group. A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab. 2012 Sep; 97: (9)3179-84.
    View PubMed
  48. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012 Jun 21; 486(7403):353-60. Epub 2012 Jun 10.
    View PubMed
  49. Savova GK, Olson JE, Murphy SP, Cafourek VL, Couch FJ, Goetz MP, Ingle JN, Suman VJ, Chute CG, Weinshilboum RM. Automated discovery of drug treatment patterns for endocrine therapy of breast cancer within an electronic medical record. J Am Med Inform Assoc. 2012 Jun; 19: (e1)e83-9.
    View PubMed
  50. Harrington SC, Weroha SJ, Reynolds C, Suman VJ, Lingle WL, Haluska P. Quantifying insulin receptor isoform expression in FFPE breast tumors. Growth Horm IGF Res. 2012 Jun-Aug; 22: (3-4)108-15.
    View PubMed
  51. Bible KC, Smallridge RC, Morris JC, Molina JR, Suman VJ, Copland JA, Rubin J, Menefee ME, Sideras K, Maples WJ, McIver B, Fatourechi V, Hay I, Foote RL, Garces YI, Kasperbauer JL, Thompson GB, Grant CS, Richards ML, Sebo T, Lloyd R, Eberhardt NL, Reddi HV, Casler JD, Karlin NJ, Westphal SA, Richardson RL, Buckner JC, Erlichman C. Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers. Am J Manag Care. 2012 May; 18(5):e162-7. Epub 2012 May 01.
    View PubMed
  52. Bible KC, Smallridge RC, Morris JC, Molina JR, Suman VJ, Copland JA, Rubin J, Menefee ME, Sideras K, Maples WJ, McIver B, Fatourechi V, Hay I, Foote RL, Garces YI, Kasperbauer JL, Thompson GB, Grant CS, Richards ML, Sebo T, Lloyd R, Eberhardt NL, Reddi HV, Casler JD, Karlin NJ, Westphal SA, Richardson RL, Buckner JC, Erlichman C. Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers. J Oncol Pract. 2012 May; 8: (3 Suppl)e1s-5s.
    View PubMed
  53. Goncalves R, Ma C, Luo J, Suman V, Ellis MJ. Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer. Nat Rev Clin Oncol. 2012 Apr; 9(4):223-9. Epub 2012 Feb 28.
    View PubMed
  54. Leontovich AA, Dronca RS, Suman VJ, Ashdown ML, Nevala WK, Thompson MA, Robinson A, Kottschade LA, Kaur JS, McWilliams RR, Ivanov LV, Croghan GA, Markovic SN. Fluctuation of systemic immunity in melanoma and implications for timing of therapy. Front Biosci (Elite Ed). 2012; 4:958-75. Epub 2012 Jan 01.
    View PubMed
  55. Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zujewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011 Dec 01; 29: (34)4491-7.
    View PubMed
  56. Moyer AM, Suman VJ, Weinshilboum RM, Avula R, Black JL, Safgren SL, Kuffel MJ, Ames MM, Ingle JN, Goetz MP. SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen. Pharmacogenomics. 2011 Nov; 12: (11)1535-43.
    View PubMed
  57. Block MS, Suman VJ, Nevala WK, Kottschade LA, Creagan ET, Kaur JS, Quevedo JF, McWilliams RR, Markovic SN. Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine. Melanoma Res. 2011 Oct; 21(5):438-45.
    View PubMed
  58. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA, Wolmark N. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011 Sep 01; 29: (25)3366-73.
    View PubMed
  59. Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, Parker JS, Luo J, DeSchryver K, Allred DC, Esserman LJ, Unzeitig GW, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Watson MA, Leitch M, Hunt K, Olson JA. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. J Clin Oncol. 2011 Jun 10; 29(17):2342-9. Epub 2011 May 09.
    View PubMed
  60. Block MS, Suman V, Kosel ML, Markovic S, Northfelt DW, Mukherjee P, McCullough AE, Pockaj BA, Nevala WK, Ingle JN, Perez EA, Gendler SJ. MUC1/HER2/neu peptide-based immunotherapeutic vaccines for breast adenocarcinomas. J Clin Oncol. 2011 May 20; 29: (15_suppl)e13046.
    View PubMed
  61. Heun JM, Nevala WK, Allred JB, Suman V, Callstrom MR, Atwell TD, Farrell MA, Galanis E, Erickson LA, Charboneau WJ, Markovic S. A pilot study of endogenous heat shock protein vaccines for metastatic melanoma. J Clin Oncol. 2011 May 20; 29: (15_suppl)8593.
    View PubMed
  62. Kottschade LA, Suman V, Perez DG, McWilliams RR, Kaur JS, Amatruda T, Geoffroy FJ, Gross HM, Cohen PA, Jaslowski AJ, Kosel ML, Markovic S. A randomized phase II trial of temozolomide (TMZ) and bevacizumab (BEV) or nab-paclitaxel (nab-P)/carboplatin (CBDCA) and bevacizumab (BEV) in patients with unresectable stage IV metastatic melanoma: A North Central Cancer Treatment Group Study (N0775). J Clin Oncol. 2011 May 20; 29: (15_suppl)8532.
    View PubMed
  63. Moley JF, Adkins D, Bible KC, Traynor AM, Molina JR, Colon-Otero G, Pluard TJ, Shah MH, Suresh R, Erlichman C, Ivy SP, Suman V, Geyer SM, Fracasso PM, Cohen MS, Tang H, Fialkowski E, Traugott A, Smallridge RC, P2C. 17-allylaminogeldanamycin in advanced medullary and differentiated thyroid carcinoma. J Clin Oncol. 2011 May 20; 29: (15_suppl)5582.
    View PubMed
  64. Kottschade LA, Suman VJ, Amatruda T 3rd, McWilliams RR, Mattar BI, Nikcevich DA, Behrens R, Fitch TR, Jaslowski AJ, Markovic SN. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1). Cancer. 2011 Apr 15; 117: (8)1704-10.
    View PubMed
  65. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris JC 3rd, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman C, Endocrine Malignancies Disease Oriented Group//Mayo Clinic Cancer Center//Mayo Phase 2 Consortium. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 2010 Oct; 11: (10)962-72.
    View PubMed
  66. Croghan GA, Suman VJ, Maples WJ, Albertini M, Linette G, Flaherty L, Eckardt J, Ma C, Markovic SN, Erlichman C. A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study. Cancer. 2010 Jul 15; 116: (14)3463-8.
    View PubMed
  67. Ellis MJ, Babiera G, Unzeitig GW, Marcom PK, Guenther JM, Deshryver FK, Allred DC, Suman V, Hunt K, Olson JA. ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer. J Clin Oncol. 2010 Jun 20; 28: (18_suppl)LBA513.
    View PubMed
  68. Litzow MR, Peethambaram PP, Safgren SL, Keeney GL, Ansell SM, Dispenzieri A, Elliott MA, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Micallef IN, Porrata LF, Lingle WL, Hartmann LC, Frost MH, Barrette BA, Long HJ, Suman VJ, Reid JM, Ames MM, Kaufmann SH. Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma. Bone Marrow Transplant. 2010 Mar; 45: (3)490-7.
    View PubMed
  69. Wang L, Ellsworth KA, Moon I, Pelleymounter LL, Eckloff BW, Martin YN, Fridley BL, Jenkins GD, Batzler A, Suman VJ, Ravi S, Dixon JM, Miller WR, Wieben ED, Buzdar A, Weinshilboum RM, Ingle JN. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res. 2010 Jan 01; 70: (1)319-28.
    View PubMed
  70. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Bolander J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009 Oct 7; 302(13):1429-36.
    View PubMed
  71. Grant CS, Ingle JN, Suman VJ, Dumesic DA, Wickerham DL, Gelber RD, Flynn PJ, Weir LM, Intra M, Jones WO, Perez EA, Hartmann LC. Menstrual cycle and surgical treatment of breast cancer: findings from the NCCTG N9431 study. J Clin Oncol. 2009 Aug 01; 27: (22)3620-6.
    View PubMed
  72. Halyard MY, Pisansky TM, Dueck AC, Suman V, Pierce L, Solin L, Marks L, Davidson N, Martino S, Kaufman P, Kutteh L, Dakhil SR, Perez EA. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol. 2009 Jun 01; 27: (16)2638-44.
    View PubMed
  73. McKean HA, Reynolds C, Hoskin TL, Suman VJ, Grant CS, Erlander MG, Ma X, Ingle J, Goetz MP. Ductal carcinoma in situ of the breast and gene expression markers for prediction of invasive recurrence. J Clin Oncol. 2009 May 20; 27: (15_suppl)550.
    View PubMed
  74. Bible KC, Smallridge RC, Maples WJ, Molina JR, Menefee ME, Suman VJ, Burton JK, Bieber CC, Ivy SP, Erlichman C, Endocrine Malignancies Disease Oriented Group//Mayo Phase 2 Consortium. Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers. J Clin Oncol. 2009 May 20; 27: (15_suppl)3521.
    View PubMed
  75. Markovic SN, Suman VJ, Kottschade LA, Amatruda T, McWilliams RR, Dakhil SR, Nikcevich DA, Morton RF, Fitch TR, Jaslowski AJ, Abraxis Bioscience LLC. A phase II trial of carboplatin (C) and nab-paclitaxel (ABI-007-nab-P) in patients with unresectable stage IV melanoma: Final data from N057E. J Clin Oncol. 2009 May 20; 27: (15_suppl)9055.
    View PubMed
  76. Allred JB, Suman V. Progression-free and overall survival analysis in patients with metastatic melanoma undergoing first- versus second-line therapy. J Clin Oncol. 2009 May 20; 27: (15_suppl)9078.
    View PubMed
  77. Quevedo F, Ashdown ML, Suman VJ, Robinson A, Kottschade LA, Kaur JS, Creagan ET, McWilliams RR, Markovic SN. Possible therapeutic reversal of immune suppression in patients with metastatic melanoma by timed delivery of temozolomide chemotherapy: A pilot study. J Clin Oncol. 2009 May 20; 27: (15_suppl)e20013.
    View PubMed
  78. Perez DG, Suman VJ, Fitch TR, Amatruda T, Morton RF, Jilani SZ, Constantinou CL, Egner JR, Kottschade LA, Markovic SN. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer. 2009 Jan 1; 115(1):119-27.
    View PubMed
  79. Kottschade LA, Suman VJ, Lowe V, Markovic SN. Positron emission tomography in early detection of relapse in high-risk melanoma patients: A retrospective review. Community Oncol. 2009; 6(8):344-7.
    View PubMed
  80. Markovic SN, Suman VJ, Nevala WK, Geeraerts L, Creagan ET, Erickson LA, Rowland KM Jr, Morton RF, Horvath WL, Pittelkow MR. A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG Study. Am J Clin Oncol. 2008 Dec; 31: (6)573-9.
    View PubMed
  81. Goetz MP, Suman VJ, Couch FJ, Ames MM, Rae JM, Erlander MG, Ma XJ, Sgroi DC, Reynolds CA, Lingle WL, Weinshilboum RM, Flockhart DA, Desta Z, Perez EA, Ingle JN. Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance. Clin Cancer Res. 2008 Sep 15; 14: (18)5864-8.
    View PubMed
  82. Suman VJ, Dueck A, Sargent DJ. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis. Cancer Invest. 2008 Jun; 26(5):439-44.
    View PubMed
  83. Maples WJ, Suman V, Croghan GA, Albertini MR, Linette G, Flaherty LE, Eckardt J, Amatruda T 3rd, Erlichman CE. Efficacy of PS-341 in combination with paclitaxel (PAC) and carboplatin (CBDCA) for the treatment of metastatic melanoma (MM): A phase II consortium study. J Clin Oncol. 2008 May 20; 26: (15_suppl)20012.
    View PubMed
  84. Goetz MP, Moyer AM, Weinshilboum RM, Suman VA, Hebbring SJ, Ames MM, Berg JC, Reynolds C, Perez EA, Ingle JN. Role of SULT1A1 copy number in tamoxifen treated breast cancer: Findings from the North Central Cancer Treatment Group (NCCTG) adjuvant trial 89-30-52. J Clin Oncol. 2008 May 20; 26: (15_suppl)22041.
    View PubMed
  85. Kottschade LA, Suman VJ, Amatruda T 3rd, McWilliams RR, Dakhil SR, Nikcevich DA, Morton RF, Fitch TR, Jaslowski AJ, Markovic SN. A phase II trial of carboplatin and ABI-007 in patients with unresectable stage IV melanoma, N057E. J Clin Oncol. 2008 May 20; 26: (15_suppl)9044.
    View PubMed
  86. Gilbert JA, Goetz MP, Reynolds CA, Ingle JN, Giordano KF, Suman VJ, Blair HE, Jenkins RB, Lingle WL, Reinholz MM, Adjei AA, Ames MM. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. Mol Cancer Ther. 2008 Apr; 7: (4)944-51.
    View PubMed
  87. Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, Martino S, Gralow JR, Dakhil SR, Ingle JN, Winer EP, Gelmon KA, Gersh BJ, Jaffe AS, Rodeheffer RJ. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008 Mar 10; 26: (8)1231-8.
    View PubMed
  88. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, Parulekar W, Markovic SN, Saxman S, Kirkwood JM. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008 Feb 1; 26(4):527-34.
    View PubMed
  89. Alberts SR, Suman VJ, Pitot HC, Camoriano JK, Rubin J. Use of KW-2189, a DNA Minor Groove-Binding Agent, in Patients with Hepatocellular Carcinoma: A North Central Cancer Treatment Group (NCCTG) Phase II Clinical Trial. Int J Gastrointest Cancer. 2008 Jan 03. [Epub ahead of print]
    View PubMed
  90. Markovic S, Suman V, Nevala W, Geeraerts L, Pittelkow M, Ingle J, Creagan E, Kaur J, Erickson L, Rowland K, Morton R, Horvath W. Autologous Anti-Tumor Immunization: A Dose-Escalation Study of Aerosolized Sargramostim (Granulocyte Macrophage Colony Stimulating Factor) in the Treatment of Metastatic Melanoma to the Lung. Am J Clin Oncol. 2008; 31:573-9.
    View PubMed
  91. Markovic SN, Suman VJ, Rao RA, Ingle JN, Kaur JS, Erickson LA, Pitot HC, Croghan GA, McWilliams RR, Merchan J, Kottschade LA, Nevala WK, Uhl CB, Allred J, Creagan ET. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol. 2007 Jun; 30(3):303-9.
    View PubMed
  92. Vachon CM, Ingle JN, Suman VJ, Scott CG, Gottardt H, Olson JE, Goss PE. Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen. Breast. 2007 Apr; 16: (2)204-10.
    View PubMed
  93. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EG, Nibbe AM, Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007 Jan; 101: (1)113-21.
    View PubMed
  94. Alberts SR, Suman VJ, Pitot HC, Camoriano JK, Rubin J. Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial. J Gastrointest Cancer. 2007; 38 (1):10-4
    View PubMed
  95. Markovic SN, Suman VJ, Ingle JN, Kaur JS, Pitot HC, Loprinzi CL, Rao RD, Creagan ET, Pittelkow MR, Allred JB, Nevala WK, Celis E. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization. Am J Clin Oncol. 2006 Aug; 29(4):352-60.
    View PubMed
  96. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, Flynn PJ, Ingle JN, Visscher D, Jenkins RB. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol. 2006 Jul 1; 24(19):3032-8.
    View PubMed
  97. Ingle JN, Suman VJ, Mailliard JA, Kugler JW, Krook JE, Michalak JC, Pisansky TM, Wold LE, Donohue JH, Goetz MP, Perez EA. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52. Breast Cancer Res Treat. 2006 Jul; 98(2):217-22. Epub 2006 Mar 15.
    View PubMed
  98. Knox SK, Ingle JN, Suman VJ, Rae JM, Flockhart DA, Zeruesenay D, Ames MM, Visscher DW, Perez EA, Goetz MP. Cytochrome P450 2D6 status predicts breast cancer relapse in women receiving adjuvant tamoxifen (Tam). J Clin Oncol. 2006 Jun 20; 24: (18_suppl)504.
    View PubMed
  99. Rao RD, Windschitl HE, Allred JB, Lowe VJ, Maples WJ, Gornet MK, Suman VJ, Creagan ET, Pitot HC, Markovic SN. Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma. J Clin Oncol. 2006 Jun 20; 24: (18_suppl)8043.
    View PubMed
  100. Markovic S, Suman V, Rao R, Creagan E, Maples W, Kaur J, McWilliams R, Allred J, Pitot H, Croghan G, Humerickhouse R. A phase II study of ABT-510 for the treatment of metastatic melanoma. J Clin Oncol. 2006 Jun 20; 24: (18_suppl)8041.
    View PubMed
  101. Goetz MP, Suman VJ, Ingle JN, Nibbe AM, Visscher DW, Reynolds CA, Lingle WL, Erlander M, Ma XJ, Sgroi DC, Perez EA, Couch FJ. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res. 2006 Apr 01; 12: (7 Pt 1)2080-7.
    View PubMed
  102. Baweja M, Suman VJ, Fitch TR, Mailliard JA, Bernath A, Rowland KM, Alberts SR, Kaur JS, Perez EA, NCCTG. Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients > or = 65 years of age: an NCCTG study. Ann Oncol. 2006 Apr; 17: (4)623-9.
    View PubMed
  103. Long HJ 3rd, Nelimark RA, Podratz KC, Suman V, Keeney GL, Nikcevich DA, Kugler JW, Rowland KM Jr, Kardinal CG, Wos EJ. Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium. Gynecol Oncol. 2006 Mar; 100(3):501-5. Epub 2005 Sep 26.
    View PubMed
  104. Ingle JN, Suman VJ, Rowland KM, Mirchandani D, Bernath AM, Camoriano JK, Fishkin PA, Nikcevich DA, Perez EA, North Central Cancer Treatment Group Trial N0032. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol. 2006 Mar 1; 24(7):1052-6.
    View PubMed
  105. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005 Dec 20; 23(36):9312-8.
    View PubMed
  106. Perez EA, Suman VJ, Rowland KM, Ingle JN, Salim M, Loprinzi CL, Flynn PJ, Mailliard JA, Kardinal CG, Krook JE, Thrower AR, Visscher DW, Jenkins RB. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005 Dec; 6(5):425-32.
    View PubMed
  107. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005 Oct 20; 353(16):1673-84.
    View PubMed
  108. Ghosh K, Melton LJ, Suman VJ, Grant CS, Sterioff S, Brandt KR, Branch C, Sellers TA, Hartmann LC. Breast biopsy utilization - A population-based study. Archives of Internal Medicine. 2005 Jul 25; 165(14):1593-8.
    View PubMed
  109. Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J, Blake C, Tlsty T, Vachon CM, Melton LJ 3rd, Visscher DW. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005 Jul 21; 353(3):229-37.
    View PubMed
  110. Baweja M, Suman V, Fitch TR, Mailliard JA, Bernath A, Rowland KM, Alberts SR, Kaur JS, Perez EA. Phase II trial of oral vinorelbine for treatment of metastatic breast cancer in women 65 years and older: N003A. J Clin Oncol. 2005 Jun; 23: (16_suppl)740.
    View PubMed
  111. Dietz AB, Markovic S, Greiner C, Maas M, Butler G, Bulur P, Suman V, Allred J, Vuk-Pavlovic S. Immunotherapy of malignant melanoma using a dendritic cell-amplified tumor RNA vaccine: A phase I study. J Clin Oncol. 2005 Jun; 23: (16_suppl)2597.
    View PubMed
  112. Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Dakhil SR, Ingle JN, Rodeheffer RJ, Gersh BJ, Hillman DW, Jaffe AS. Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial. J Clin Oncol. 2005 Jun; 23: (16_suppl)556.
    View PubMed
  113. Reinholz MM, Nibbe A, Jonart LM, Kitzmann K, Suman VJ, Ingle JN, Houghton R, Zehentner B, Roche PC, Lingle WL. Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer. Clin Cancer Res. 2005 May 15; 11(10):3722-32.
    View PubMed
  114. Ingle JN, Suman VJ. Aromatase inhibitors for therapy of advanced breast cancer. J Steroid Biochem Mol Biol. 2005 May; 95: (1-5)113-9.
    View PubMed
  115. Lafky JM, Baron AT, Cora EM, Hillman DW, Suman VJ, Perez EA, Ingle JN, Maihle NJ. Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole. Cancer Res. 2005 Apr 15; 65(8):3059-62.
    View PubMed
  116. Dowdy SC, Metzinger DS, Gebhart JB, Srivatsa P, Haddock MG, Suman VJ, Podratz KC. Salvage whole-abdominal radiation therapy after second-look laparotomy or secondary debulking surgery in patients with ovarian cancer. Gynecol Oncol. 2005 Feb; 96(2):389-94.
    View PubMed
  117. Perez EA, Suman VJ, Fitch TR, Mailliard JA, Ingle JN, Cole JT, Veeder MH, Flynn PJ, Walsh DJ, Addo FK. A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932. Oncology. 2005; 69(2):117-21. Epub 2005 Aug 23.
    View PubMed
  118. Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Dakhil SR, Ingle JN, Rodeheffer RJ, Gersh BJ, Jaffe AS. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol. 2004 Sep 15; 22(18):3700-4.
    View PubMed
  119. Markovic SN, Suman VJ, Dalton RJ, Allred JB, Nevala WK, Celis E, Alberts SR, Fitch TR, Egner JR, Ebbert LP. A phase II study of aerosolized GM-CSF in the treatment of metastatic melanoma to the lung. J Clin Oncol. 2004 Jul 15; 22: (14_suppl)7571.
    View PubMed
  120. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, Flynn PJ, Ingle JN, Visscher D, Jenkins RB. HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial. J Clin Oncol. 2004 Jul 15; 22: (14_suppl)567.
    View PubMed
  121. Reinholz MM, An MW, Johnsen SA, Subramaniam M, Suman VJ, Ingle JN, Roche PC, Spelsberg TC. Differential gene expression of TGF beta inducible early gene (TIEG), Smad7, Smad2 and Bard1 in normal and malignant breast tissue. Breast Cancer Res Treat. 2004 Jul; 86: (1)75-88.
    View PubMed
  122. Miller DV, Leontovich AA, Lingle WL, Suman VJ, Mertens ML, Lillie J, Ingalls KA, Perez EA, Ingle JN, Couch FJ, Visscher DW. Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomas. Mod Pathol. 2004 Jul; 17(7):756-64.
    View PubMed
  123. Perez E, Suman V, Davidson N, Kaufman P, Martino S, Dakhil S, Rodeheffer R, Gersh B, Jaffe A. Effect of Dozorubicin Plus Cyclophosphamide on Left Ventricular Ejection Fraction in Patients With Breast Cancer in the NCCTG N9831 Intergroup Adjuvant Trial J Clin Pathol. 2004; 22:3700-3704.
    View PubMed
  124. Dowdy SC, Constantinou CL, Hartmann LC, Keeney GL, Suman VJ, Hillman DW, Podratz KC. Long-term follow-up of women with ovarian cancer after positive second-look laparotomy. Gynecol Oncol. 2003 Dec; 91(3):563-8.
    View PubMed
  125. Ingle JN, Suman VJ. Aromatase inhibitors versus tamoxifen for management of postmenopausal breast cancer in the advanced disease and neoadjuvant settings. J Steroid Biochem Mol Biol. 2003 Sep; 86(3-5):313-9.
    View PubMed
  126. Jatoi A, Suman VJ, Schaefer P, Block M, Loprinzi C, Roche P, Garneau S, Morton R, Stella PJ, Alberts SR, Pittelkow M, Sloan J, Pagano R. A phase II study of topical ceramides for cutaneous breast cancer. Breast Cancer Res Treat. 2003 Jul; 80(1):99-104.
    View PubMed
  127. Korndorfer SR, Lucas AR, Suman VJ, Crowson CS, Krahn LE, Melton LJ 3rd. Long-term survival of patients with anorexia nervosa: a population-based study in Rochester, Minn. Mayo Clin Proc. 2003 Mar; 78(3):278-84.
    View PubMed
  128. Markovic S, Suman V, Dalton R, Allred J, Wettstein P, Nevala W, Celis E, Alberts S, Fitch T, Egner J, Ebberts L, Tschetter L. A Phase II Study of Aerosolized GM-CSF in the Treatm Cancer. 2003.
    View PubMed
  129. Long HJ 3rd, Rayson S, Podratz KC, Abu-Ghazaleh S, Suman V, Hartmann LC, Levitt R, Nair S, Hatfield AK, Knost JA. Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin, and cisplatin with or without the addition of molgramostim, and review of the literature. Am J Clin Oncol. 2002 Dec; 25(6):547-51.
    View PubMed
  130. Markovic S, Suman VJ, Dalton RJ, Woods JE, Fitzgibbons RJ Jr, Wold LE, Buckner JC, Kugler JW, Mailliard JA, Rowland KM, Krook JE, Brown DW, Tirona MT, Creagan ET. Randomized, placebo-controlled, phase III surgical adjuvant clinical trial of megestrol acetate (Megace) in selected patients with malignant melanoma. Am J Clin Oncol. 2002 Dec; 25(6):552-6.
    View PubMed
  131. Pisansky TM, Blute ML, Hillman DW, Davis BJ, Haddock MG, Suman VJ, Wilson TM, Zincke H. The relevance of prostatectomy findings for brachytherapy selection in patients with localized prostate carcinoma. Cancer. 2002 Aug 1; 95(3):513-9.
    View PubMed
  132. Perez EA, Geeraerts L, Suman VJ, Adjei AA, Baron AT, Hatfield AK, Maihle N, Michalak JC, Kuross SA, Kugler JW, Lafky JM, Ingle JN. A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer. Ann Oncol. 2002 Aug; 13: (8)1225-35.
    View PubMed
  133. Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, Addo FK, Murphy B, Ingle JN, Perez EA. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst. 2002 Jun 5; 94(11):855-7.
    View PubMed
  134. Markovic SN, Suman VJ, Vukov AM, Fitch TR, Hillman DW, Adjei AA, Alberts SR, Kaur JS, Braich TA, Creagan ET. Phase II trial of KW2189 in patients with advanced malignant melanoma. Am J Clin Oncol. 2002 Jun; 25(3):308-12.
    View PubMed
  135. Witzig TE, Bossy B, Kimlinger T, Roche PC, Ingle JN, Grant C, Donohue J, Suman VJ, Harrington D, Torre-Bueno J, Bauer KD. Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin Cancer Res. 2002 May; 8(5):1085-91.
    View PubMed
  136. Okuno SH, Mailliard JA, Suman VJ, Edmonson JH, Creagan ET, Nair S, Levitt R, Kugler JW. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck. Cancer. 2002 Apr 15; 94(8):2224-31.
    View PubMed
  137. Maihle NJ, Lafky JM, Baron AT, Boardman CH, Greenwood TM, Christensen TA, Reiter JL, Cora EM, Lee H, Suman VJ, Fishman DA, Perez EA, Podratz KC. EGF receptor/ErbB isoforms as serum biomarkers in breast and ovarian cancer. Journal of Clinical Ligand Assay. 2002 Spr; 25(1):57-60.
    View PubMed
  138. Long HJ, Rayson S, Podratz KC, Abu-Ghazaleh S, Suman V, Buckner JC, Levitt R, Nair S, Hatfield AK, Kugler JW. Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with or without the addition of molgramostim in women with advanced/recurrent cervix cancer. American Journal of Clinical Oncology. 2002; 25(6):547-551.
  139. Roche P, Suman V, Jenkins R, Davidson N, Martino S, Kaufman P, Addo F, Murphy B, Ingle J, Perez E. Determination of HER-2 Status for the Breast Intergroup Trial N9831: Concordance Between Local and Central Laboratory Testing and the Correlation of Overexpression and Amplification Journal of the National Cancer Institute. 2002; 94:855-857.
    View PubMed
  140. Baron AT, Lafky JM, Suman VJ, Hillman DW, Buenafe MC, Boardman CH, Podratz KC, Perez EA, Maihle NJ. A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women. Cancer Epidemiol Biomarkers Prev. 2001 Nov; 10(11):1175-85.
    View PubMed
  141. Gostout BS, Hartmann LC, Suman VJ, Fay NE, Jefferies JA, Morton RF, Gaffey TA, Farr GH Jr, Tschetter LK, Abu-Ghazaleh S, Gallenberg MM, Hatfield AK. A randomized trial of interferon-alpha in cervical dysplasia. Int J Gynaecol Obstet. 2001 Aug; 74: (2)207-10.
    View PubMed
  142. Schneekloth TD, Morse RM, Herrick LM, Suman VJ, Offord KP, Davis LJ Jr. Point prevalence of alcoholism in hospitalized patients: continuing challenges of detection, assessment, and diagnosis. Mayo Clin Proc. 2001 May; 76(5):460-6.
    View PubMed
  143. Edmonson JH, Suman VJ, Dalton RJ, Bro WC, Gallenberg MM, Long HJ, Levitt R, Hatfield AK, Krook JE, Mailliard JA, Gerstner JB, North Central Cancer Treatment Group. Comparison of conventional dose and double dose carboplatin in patients receiving cyclophosphamide plus carboplatin for advanced ovarian carcinoma: a North Central Cancer Treatment Group Study. Cancer Invest. 2001; 19: (6)597-602.
    View PubMed
  144. Hanson Frost M, Suman VJ, Rummans TA, Dose AM, Taylor M, Novotny P, Johnson R, Evans RE. Physical, psychological and social well-being of women with breast cancer: the influence of disease phase. Psychooncology. 2000 May-Jun; 9(3):221-31.
    View PubMed
  145. Frost MH, Walsh Vockley C, Suman VJ, Greene MH, Zahasky K, Hartmann L. Perceived familial risk of cancer: health concerns and psychosocial adjustment. J Psychosoc Oncol. 2000; 18(1):63-82.
    View PubMed
  146. Madson TJ, Youdas JW, Suman VJ. Reproducibility of lumbar spine range of motion measurements using the back range of motion device. J Orthop Sports Phys Ther. 1999 Aug; 29(8):470-7.
    View PubMed
  147. Ingle JN, Suman VJ, Johnson PA, Krook JE, Mailliard JA, Wheeler RH, Loprinzi CL, Perez EA, Jordan VC, Dowsett M. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer. Clin Cancer Res. 1999 Jul; 5(7):1642-9.
    View PubMed
  148. Maguire-Boston EK, Suman V, Jacobsen SJ, Moore SB, Habermann TM, Cerhan JR, Folsom AR. Blood transfusion and risk of non-Hodgkin's lymphoma. Am J Epidemiol. 1999 Jun 15; 149(12):1113-8.
    View PubMed
  149. Ingle JN, Suman VJ, Jordan VC, Dowsett M. Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer. Endocr Relat Cancer. 1999 Jun; 6(2):265-9.
    View PubMed
  150. Creagan ET, Suman VJ, Dalton RJ, Pitot HC, Long HJ, Veeder MH, Vukov AM, Rowland KM, Krook JE, Michalak JC. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol. 1999 Jun; 17: (6)1884-90.
    View PubMed
  151. Rayson D, Adjei AA, Suman VJ, Wold LE, Ingle JN. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol. 1999 Apr; 10: (4)413-9.
    View PubMed
  152. Ingle JN, Suman VJ, Kardinal CG, Krook JE, Mailliard JA, Veeder MH, Loprinzi CL, Dalton RJ, Hartmann LC, Conover CA, Pollak MN. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer. 1999 Mar 15; 85: (6)1284-92.
    View PubMed
  153. Peethambaram PP, Ingle JN, Suman VJ, Hartmann LC, Loprinzi CL. Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat. 1999 Mar; 54(2):117-22.
    View PubMed
  154. Baron AT, Lafky JM, Boardman CH, Balasubramaniam S, Suman VJ, Podratz KC, Maihle NJ. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 1999 Feb; 8(2):129-37.
    View PubMed
  155. Madison TJ, Youdas JW, Suman VJ, Hanson TJ. Reproducibility measurements of lumbar spine range of motion: A comparison of two methods. JOurnal of Orthopedic and Sports Physical Therapy. 1999; 29(8):470-477.
  156. Rayson D, Erlichman C, Suman VJ, Roche PC, Wold LE, Ingle JN, Donohue JH. Molecular markers in male breast carcinoma. Cancer. 1998 Nov 1; 83(9):1947-55.
    View PubMed
  157. Stafford SL, Perry A, Suman VJ, Meyer FB, Scheithauer BW, Lohse CM, Shaw EG. Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc. 1998 Oct; 73(10):936-42.
    View PubMed
  158. Creagan ET, Veeder MH, Suman VJ, Burch PA, Maples WJ, Schaefer PL, Pfeifle DM, Dalton RJ, Hatfield AK, Poon MA. A phase II study of high-dose cimetidine and the combination 5-fluorouracil, interferon alpha-2A, and leucovorin in advanced renal cell adenocarcinoma. Am J Clin Oncol. 1998 Oct; 21: (5)475-8.
    View PubMed
  159. Baron AT, Lafky JM, Connolly DC, Peoples J, O'Kane DJ, Suman VJ, Boardman CH, Podratz KC, Maihle NJ. A sandwich type acridinium-linked immunosorbent assay (ALISA) detects soluble ErbB1 (sErbB1) in normal human sera. J Immunol Methods. 1998 Oct 1; 219(1-2):23-43.
    View PubMed
  160. Rummans TA, Frost M, Suman VJ, Taylor M, Novotny P, Gendron T, Johnson R, Hartmann L, Dose AM, Evans RW. Quality of life and pain in patients with recurrent breast and gynecologic cancer. Psychosomatics. 1998 Sep-Oct; 39(5):437-45.
    View PubMed
  161. Stafford SL, Perry A, Leavitt JA, Garrity JA, Suman VJ, Scheithauer BW, Lohse CM, Meyer FB. Anterior visual pathway meningiomas primarily resected between 1978 and 1988: the Mayo Clinic Rochester experience. J Neuroophthalmol. 1998 Sep; 18(3):206-10.
    View PubMed
  162. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas. Cancer. 1998 Jun 1; 82(11):2262-9.
    View PubMed
  163. Orvidas LJ, Olsen KD, Lewis JE, Suman VJ. Verrucous carcinoma of the larynx: a review of 53 patients. Head & Neck. 1998 May; 20(3):197-203.
    View PubMed
  164. Yawn BP, Suman VJ, Jacobsen SJ. Maternal recall of distant pregnancy events. J Clin Epidemiol. 1998 May; 51(5):399-405.
    View PubMed
  165. Creagan ET, Hestorff RD, Suman VJ, Mailliard JA, Nair S, Krook JE, Kugler JW, Marschke RF Jr, Michalak JC, Tschetter LK. Combined levamisole with recombinant interleukin-2 (IL-2) in patients with advanced renal cell carcinoma: a phase II study. Am J Clin Oncol. 1998 Apr; 21(2):139-41.
    View PubMed
  166. Schiff D, Suman VJ, Yang P, Rocca WA, O'Neill BP. Risk factors for primary central nervous system lymphoma: a case-control study. Cancer. 1998 Mar 1; 82(5):975-82.
    View PubMed
  167. Moellentine C, Rummans T, Ahlskog JE, Harmsen WS, Suman VJ, O'Connor MK, Black JL, Pileggi T. Effectiveness of ECT in patients with parkinsonism. Journal of Neuropsychiatry & Clinical Neurosciences. 1998 Spring; 10(2):187-93.
    View PubMed
  168. Lundahl RE, Foote RL, Bonner JA, Suman VJ, Lewis JE, Kasperbauer JL, McCaffrey TV, Olsen KD. Combined neck dissection and postoperative radiation therapy in the management of the high-risk neck: a matched-pair analysis. Int J Radiat Oncol Biol Phys. 1998 Feb 1; 40(3):529-34.
    View PubMed
  169. Suman VJ, Van Winter JT, Evans MP, Simmons PS, Jacobsen SJ, Manolis AL. Levonorgestrel contraceptive implants in female patients 14 to 21 years old. Mayo Clin Proc. 1998 Jan; 73(1):10-6.
    View PubMed
  170. Creagan E, Hestorff R, Suman V, Mailliard J, Nair S, Krook J, Kugler J, Marschke R, Michalak J, Tschetter L. A phase II study of combined Levamisole with recombinant Interleukin-2 (IL-2) in patients with advanced renal cell carcinoma Am J Clin Oncol. 1998; 21 (2):139-141.
    View PubMed
  171. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol. 1997 Dec; 21(12):1455-65.
    View PubMed
  172. Aust MR, Olsen KD, Lewis JE, Nascimento AG, Meland NB, Foote RL, Suman VJ. Angiosarcomas of the head and neck: clinical and pathologic characteristics. Ann Otol Rhinol Laryngol. 1997 Nov; 106: (11)943-51.
    View PubMed
  173. Krahn LE, Reese MM, Rummans TA, Peterson GC, Suman VJ, Sharbrough FW, Cascino GD. Health care utilization of patients with psychogenic nonepileptic seizures. Psychosomatics. 1997 Nov-Dec; 38(6):535-42.
    View PubMed
  174. Houston MS, Silverstein MD, Suman VJ. Risk factors for 30-day mortality in elderly patients with lower respiratory tract infection. Community-based study. Arch Intern Med. 1997 Oct 27; 157(19):2190-5.
    View PubMed
  175. Lawrence JB, Conover CA, Haddad TC, Ingle JN, Reid JM, Ames MM, Suman VJ, Marks RS, Erlichman C, Hartmann LC. Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins. Clin Cancer Res. 1997 Oct; 3(10):1713-20.
    View PubMed
  176. Barrette BA, Srivatsa PJ, Cliby WA, Keeney GL, Suman VJ, Podratz KC, Roche PC. Overexpression of p34cdc2 protein kinase in epithelial ovarian carcinoma. Mayo Clin Proc. 1997 Oct; 72(10):925-9.
    View PubMed
  177. Creagan ET, Rowland KM Jr, Suman VJ, Kardinal CG, Marschke RF Jr, Marks RS, Maples WJ. Phase II study of combined levamisole with recombinant interleukin-2 in patients with advanced malignant melanoma. Am J Clin Oncol. 1997 Oct; 20(5):490-2.
    View PubMed
  178. Srivatsa PJ, Cliby WA, Keeney GL, Suman VJ, Harmsen WS, Ziesmer SC, Roche PC, Podratz KC. Expression of nm23/nucleoside diphosphate kinase-A protein in endometrial carcinoma. Gynecol Oncol. 1997 Aug; 66(2):238-45.
    View PubMed
  179. Schiff D, O'Neill BP, Suman VJ. Spinal epidural metastasis as the initial manifestation of malignancy: clinical features and diagnostic approach. Neurology. 1997 Aug; 49(2):452-6.
    View PubMed
  180. Ingle JN, Johnson PA, Suman VJ, Gerstner JB, Mailliard JA, Camoriano JK, Gesme DH Jr, Loprinzi CL, Hatfield AK, Hartmann LC. A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. Cancer. 1997 Jul 15; 80(2):218-24.
    View PubMed
  181. Ania BJ, Suman VJ, Fairbanks VF, Rademacher DM, Melton LJ. Incidence of anemia in older people: an epidemiologic study in a well defined population. J Am Geriatr Soc. 1997 Jul; 45(7):825-31.
    View PubMed
  182. Dhodapkar M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC, Ames MM, Suman VJ. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res. 1997 Jul; 3: (7)1093-100.
    View PubMed
  183. Hartmann LC, Tschetter LK, Habermann TM, Ebbert LP, Johnson PS, Mailliard JA, Levitt R, Suman VJ, Witzig TE, Wieand HS, Miller LL, Moertel CG. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med. 1997 Jun 19; 336(25):1776-80.
    View PubMed
  184. Gray DT, Suman VJ, Su WP, Clay RP, Harmsen WS, Roenigk RK. Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992. Arch Dermatol. 1997 Jun; 133(6):735-40.
    View PubMed
  185. Ingle JN, Kardinal CG, Suman VJ, Veeder MH, Schaefer PL, Kirschling RJ, Mailliard JA. Mitoxantrone dose augmentation utilizing filgrastim support in combination with fixed-dose 5-fluorouracil and leucovorin in women with metastatic breast cancer. Breast Cancer Res Treat. 1997 May; 43(3):193-200.
    View PubMed
  186. Ingle JN, Twito DI, Suman VJ, Krook JE, Maillard JA, Windschitl HE, Marschke RF Jr. Evaluation of intravenous 6-thioguanine as first-line chemotherapy in women with metastatic breast cancer. Am J Clin Oncol. 1997 Feb; 20(1):69-72.
    View PubMed
  187. Olsen KD, Lewis JE, Suman VJ. Spindle cell carcinoma of the larynx and hypopharynx. Otolaryngol Head Neck Surg. 1997 Jan; 116: (1)47-52.
    View PubMed
  188. Pollak M, Ingle J, Suman VJ, Kugler J. Adjuvant therapy of cancer VIII In: SE Salmon (ed). Proceedings of the Eighth International Conference on the Adjuvant Therapy of Cancer JB Lippincott. 1997.
  189. Olsen KD, Meland NB, Aust MR, Lewis JE, Foote RL, Nascimento AG, Suman VJ. Angiosarcomas of the head and neck. Annals of Oncology Rhinology and Laryngology ,. 1997; 106: (11)943-51.
  190. Barrette B, Srivatsa P, Cliby W, Keeney G, Suman V, Podratz K, Roche P. Over-expression of p34(cdc2) protein kinase in epithelial ovarian carcinoma. Mayo Clin Proc. 1997; 72(10):925-929.
    View PubMed
  191. Noyes WS, McCaffrey TV, Fabry DA, Robinette MS, Suman VJ. Effect of temperature elevation on rabbit cochlear function as measured by distortion-product otoacoustic emissions. Otolaryngol Head Neck Surg. 1996 Dec; 115: (6)548-52.
    View PubMed
  192. Glikson M, von Feldt LK, Suman VJ, Hayes DL. Short- and long-term results with an active-fixation, bipolar, polyurethane-insulated atrial pacing lead. Pacing Clin Electrophysiol. 1996 Oct; 19(10):1469-73.
    View PubMed
  193. Pisansky TM, Blute ML, Suman VJ, Bostwick DG, Earle JD, Zincke H. Correlation of pretherapy prostate cancer characteristics with seminal vesicle invasion in radical prostatectomy specimens. Int J Radiat Oncol Biol Phys. 1996 Oct 1; 36(3):585-91.
    View PubMed
  194. Youdas JW, Garrett TR, Harmsen S, Suman VJ, Carey JR. Lumbar lordosis and pelvic inclination of asymptomatic adults. Phys Ther. 1996 Oct; 76(10):1066-81.
    View PubMed
  195. Farnell GF, Buckner JC, Cascino TL, O'Connell MJ, Schomberg PJ, Suman V. Brain metastases from colorectal carcinoma. The long term survivors. Cancer. 1996 Aug 15; 78(4):711-6.
    View PubMed
  196. Miller CD, Laskowski ER, Suman VJ. Effect of corrective rearfoot orthotic devices on ground reaction forces during ambulation. Mayo Clin Proc. 1996 Aug; 71(8):757-62.
    View PubMed
  197. Hamel NW, Sebo TJ, Wilson TO, Keeney GL, Roche PC, Suman VJ, Hu TC, Podratz KC. Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma. Gynecol Oncol. 1996 Aug; 62(2):192-8.
    View PubMed
  198. Srivatsa PJ, Cliby WA, Keeney GL, Dodson MK, Suman VJ, Roche PC, Podratz KC. Elevated nm23 protein expression is correlated with diminished progression-free survival in patients with epithelial ovarian carcinoma. Gynecol Oncol. 1996 Mar; 60(3):363-72.
    View PubMed
  199. Foote RL, Grado GL, Buskirk SJ, Olsen KD, Bonner JA, Earle JD, Kasperbauer JL, McCaffrey TV, Suman VJ. Radiation therapy for glottic cancer using 6-MV photons. Cancer. 1996 Jan 15; 77(2):381-6.
    View PubMed
  200. Pisansky TM, Zincke H, Suman VJ, Bostwick DG, Earle JD, Oesterling JE. Correlation of pretherapy prostate cancer characteristics with histologic findings from pelvic lymphadenectomy specimens. Int J Radiat Oncol Biol Phys. 1996 Jan 01; 34 (1):33-9
    View PubMed
  201. Ingle JN, Kardinal CG, Suman VJ, Krook JE, Hatfield AK. Octreotide as first-line treatment for women with metastatic breast cancer. Invest New Drugs. 1996; 14 (2):235-7
    View PubMed
  202. Rasmussen NH, Colligan RC, Suman VJ. An investigation of clinic-based laboratory measures in the differential diagnosis of attention-deficit hyperactivity disorder (ADHD) versus externalizing disruptive behavior disorder. Archives of clinical Neuropsychology. 1996; 11(5):439-440.
  203. Lynn S, Pool A, Rose D, Brey R, Suman V. Randomized trial of the canalith repositioning procedure. Otolaryngol Head Neck Surg. 1995 Dec; 113: (6)712-20.
    View PubMed
  204. Carey JR, Bogard CL, Youdas JW, Suman VJ. Stimulus-response compatibility effects in a manual tracking task. Percept Mot Skills. 1995 Dec; 81(3 Pt 2):1155-70.
    View PubMed
  205. Houston MS, Silverstein MD, Suman VJ. Community-acquired lower respiratory tract infection in the elderly: a community-based study of incidence and outcome. J Am Board Fam Pract. 1995 Sep-Oct; 8: (5)347-56.
    View PubMed
  206. Soundy TJ, Lucas AR, Suman VJ, Melton LJ. Bulimia nervosa in Rochester, Minnesota from 1980 to 1990. Psychol Med. 1995 Sep; 25(5):1065-71.
    View PubMed
  207. Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ 3rd. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc. 1995 Jul; 70(7):628-33.
    View PubMed
  208. Brey RH, Facer GW, Trine MB, Lynn SG, Peterson AM, Suman VJ. Vestibular effects associated with implantation of a multiple channel cochlear prosthesis. Am J Otol. 1995 Jul; 16(4):424-30.
    View PubMed
  209. Evans MP, Webb MJ, Gaffey TA, Katzmann JA, Suman VJ, Hu TC. DNA ploidy of ovarian granulosa cell tumors. Lack of correlation between DNA index or proliferative index and outcome in 40 patients. Cancer. 1995 May 1; 75(9):2295-8.
    View PubMed
  210. Hayes DL, Graham KJ, Irwin M, Vidaillet H, Disler G, Sweesy M, Kincaid D, Osborn MJ, Suman VJ, Neubauer SA. Multicenter experience with a bipolar tined polyurethane ventricular lead. Pacing & Clinical Electrophysiology. 1995 May; 18(5 Pt 1):999-1004.
    View PubMed
  211. Tomlinson FH, Kurtin PJ, Suman VJ, Scheithauer BW, O'Fallon JR, Kelly PJ, Jack CR Jr, O'Neill BP. Primary intracerebral malignant lymphoma: a clinicopathological study of 89 patients. J Neurosurg. 1995 Apr; 82(4):558-66.
    View PubMed
  212. Reeder GS, Bryant SC, Suman VJ, Holmes DR Jr. Intracoronary thrombus: still a risk factor for PTCA failure? Cathet Cardiovasc Diagn. 1995 Mar; 34: (3)191-5.
    View PubMed
  213. Thomson SP, Gibbons RJ, Smars PA, Suman VJ, Pierre RV, Santrach PJ, Jiang NS. Incremental value of the leukocyte differential and the rapid creatine kinase-MB isoenzyme for the early diagnosis of myocardial infarction. Ann Intern Med. 1995 Mar 1; 122(5):335-41.
    View PubMed
  214. Youdas JW, Suman VJ, Garrett TR. Reliability of measurements of lumbar spine sagittal mobility obtained with the flexible curve. J Orthop Sports Phys Ther. 1995 Jan; 21(1):13-20.
    View PubMed
  215. Crotty TB, Li CY, Edwards WD, Suman VJ. Amyloidosis and endomyocardial biopsy: Correlation of extent and pattern of deposition with amyloid immunophenotype in 100 cases. Cardiovasc Pathol. 1995 Jan-Mar; 4(1):39-42.
    View PubMed
  216. Baron AT, Suman VJ, Nemeth E, Salisbury JL. The pericentriolar lattice of PtK2 cells exhibits temperature and calcium-modulated behavior. J Cell Sci. 1994 Nov; 107 ( Pt 11):2993-3003.
    View PubMed
  217. Youdas JW, Carey JR, Garrett TR, Suman VJ. Reliability of goniometric measurements of active arm elevation in the scapular plane obtained in a clinical setting. Arch Phys Med Rehabil. 1994 Oct; 75(10):1137-44.
    View PubMed
  218. Ania BJ, Suman VJ, Sobell JL, Codd MB, Silverstein MN, Melton LJ. Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989. Am J Hematol. 1994 Oct; 47(2):89-93.
    View PubMed
  219. Foote RL, Olsen KD, Buskirk SJ, Stanley RJ, Suman VJ. Laryngectomy alone for T3 glottic cancer. Head Neck. 1994 Sep-Oct; 16(5):406-12.
    View PubMed
  220. Thomas JV, Olsen KD, Neel HB 3rd, DeSanto LW, Suman VJ. Recurrences after endoscopic management of early (T1) glottic carcinoma. Laryngoscope. 1994 Sep; 104(9):1099-104.
    View PubMed
  221. Glikson M, Vonfeldt LK, Suman VJ, Hayes DL. Clinical surveillance of an active fixation, bipolar, polyurethane insulated pacing lead. 2. The ventricular lead. Pacing Clin Electrophysiol. 1994 Sep; 17:1499-1502.
    View PubMed
  222. Carey JR, Bogard CL, King BA, Suman VJ. Finger-movement tracking scores in healthy subjects. Perceptual & Motor Skills. 1994 Aug; 79(1 Pt 2):563-76.
    View PubMed
  223. Ania BJ, Suman VJ, Fairbanks VF, Melton LJ 3rd. Prevalence of anemia in medical practice: community versus referral patients. Mayo Clin Proc. 1994 Aug; 69 (8):730-5
    View PubMed
  224. Glikson M, Vonfeldt LK, Suman VJ, Hayes DL. Clinical surveillance of an active fixation, bipolar, polyurethane insulated pacing lead. 1. The atrial lead. Pacing Clin Electrophysiol. 1994 Aug; 17:1399-1404.
    View PubMed
  225. Thomas JV, Olsen KD, Neel HB 3rd, DeSanto LW, Suman VJ. Early glottic carcinoma treated with open laryngeal procedures. Archives of Otolaryngology -- Head & Neck Surgery. 1994 Mar; 120(3):264-8.
    View PubMed
  226. Stormont TJ, Suman VJ, Oesterling JE. Newly diagnosed bulbar urethral strictures: etiology and outcome of various treatments. J Urol. 1993 Nov; 150 (5 Pt 2):1725-8
    View PubMed
  227. Oesterling JE, Suman VJ, Zincke H, Bostwick DG. PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors. Urol Clin North Am. 1993 Nov; 20(4):687-93.
    View PubMed
  228. Suman VJ, Atkinson EJ, O'Fallon WM, Black DM, Melton LJ 3rd. A nomogram for predicting lifetime hip fracture risk from radius bone mineral density and age. Bone. 1993 Nov-Dec; 14(6):843-6.
    View PubMed
  229. Youdas JW, Bogard CL, Suman VJ. Reliability of goniometric measurements and visual estimates of ankle joint active range of motion obtained in a clinical setting. Arch Phys Med Rehabil. 1993 Oct; 74(10):1113-8.
    View PubMed
  230. Suman VJ, Tazelaar HD, Bailey K, Melton J, Longaker MT, Stern R, Finkbeiner WE. Are patients with neoplasia at an increased risk for cardiac myxomas? Hum Pathol. 1993 Sep; 24(9):1008-11.
    View PubMed
  231. Foote RL, Robinow JS, Shaw EG, Kline RW, Suman VJ, Ilstrup DM, Lee RE. Low-versus high-energy photon beams in radiotherapy for lung cancer. Med Dosim. 1993 Summer; 18(2):65-72.
  232. Cersosimo E, Gharib H, Suman VJ, Goellner JR. "Suspicious" thyroid cytologic findings: outcome in patients without immediate surgical treatment. Mayo Clin Proc. 1993 Apr; 68 (4):343-8
    View PubMed
  233. Oesterling JE, Andrews PE, Suman VJ, Zincke H, Myers RP. Preoperative androgen deprivation therapy: artificial lowering of serum prostate specific antigen without downstaging the tumor. J Urol. 1993 Apr; 149 (4):779-82
    View PubMed
  234. Olsen KD, Thomas JV, DeSanto LW, Suman VJ. Indications and results of cordectomy for early glottic carcinoma. Otolaryngol Head Neck Surg. 1993 Mar; 108: (3)277-82.
    View PubMed
  235. O'Brien T, Gharib H, Suman VJ, van Heerden JA. Treatment of toxic solitary thyroid nodules: surgery versus radioactive iodine. Surgery. 1992 Dec; 112(6):1166-70.
    View PubMed
  236. Youdas JW, Garrett TR, Suman VJ, Bogard CL, Hallman HO, Carey JR. Normal range of motion of the cervical spine: an initial goniometric study. Phys Ther. 1992 Nov; 72(11):770-80.
    View PubMed